# Josep Tabernero

Source: https://onco.cc/people/josep-tabernero/  
OnCo record `josep-tabernero` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Colorectal cancer trialist who led BEACON and BREAKWATER, bringing targeted therapy to BRAF-mutant disease; former ESMO President.

## Summary

Josep Tabernero is Director of the Vall d'Hebron Institute of Oncology (VHIO) and Head of Medical Oncology at Vall d'Hebron University Hospital in Barcelona, and served as President of the European Society for Medical Oncology (ESMO) in 2018-2019. His specialisms are colorectal cancer, gastrointestinal oncology, early drug development and precision medicine, with a focus on BRAF and EGFR. He led BEACON CRC, the New England Journal of Medicine trial of encorafenib, binimetinib and cetuximab in BRAF V600E-mutated colorectal cancer, and BREAKWATER, which combined encorafenib and cetuximab with mFOLFOX6 and established first-line targeted therapy for BRAF-mutant disease. His VHIO profile and PubMed listing are linked.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Vall d'Hebron Institute of Oncology (VHIO); Head of Medical Oncology, Vall d'Hebron University Hospital
- Specialisms: Colorectal cancer; Gastrointestinal oncology; Early drug development; Precision medicine

## Sources

- VHIO: https://vhio.net/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Tabernero%20J%5BAuthor%5D%20colorectal

## Connected records

- cancers: [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- targets: [BRAF](https://onco.cc/targets/braf/), [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Encorafenib](https://onco.cc/drugs/encorafenib/)
- institutions: [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/), [Vall d'Hebron University Hospital / VHIO](https://onco.cc/institutions/vall-dhebron/)
- trials: [BEACON CRC](https://onco.cc/trials/beacon-crc/), [BREAKWATER](https://onco.cc/trials/breakwater/)
- key papers: [BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer](https://onco.cc/key-papers/paper-breakwater-nejm-2025/), [Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON CRC)](https://onco.cc/key-papers/paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019/), [Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020/), [Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023/), [Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)](https://onco.cc/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/), [Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)](https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/), [Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials](https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/), [Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)](https://onco.cc/key-papers/paper-mayer-recourse-tas-102-nejm-2015/), [Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)](https://onco.cc/key-papers/paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/josep-tabernero.json